These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26729948)

  • 21. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
    Reneerkens OA; Rutten K; Steinbusch HW; Blokland A; Prickaerts J
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):419-43. PubMed ID: 18709359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural and Synthetic Phosphodiesterase Inhibitors in 2023: an Update on the Impact on Neurological and Psychiatric Conditions.
    Ribaudo G; Gianoncelli A
    Mini Rev Med Chem; 2024; 24(6):568-570. PubMed ID: 37817520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benzodiazepines in psychiatry.
    Swanson DA
    S Afr Med J; 1975 Oct; 49(44):1829-34. PubMed ID: 242083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
    Lipina TV; Palomo V; Gil C; Martinez A; Roder JC
    Neuropharmacology; 2013 Jan; 64():205-14. PubMed ID: 22749842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphodiesterase inhibition in cognitive decline.
    García-Barroso C; Ugarte A; Martínez M; Rico AJ; Lanciego JL; Franco R; Oyarzabal J; Cuadrado-Tejedor M; García-Osta A
    J Alzheimers Dis; 2014; 42 Suppl 4():S561-73. PubMed ID: 25125473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development.
    Jeon YH; Heo YS; Kim CM; Hyun YL; Lee TG; Ro S; Cho JM
    Cell Mol Life Sci; 2005 Jun; 62(11):1198-220. PubMed ID: 15798894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PDEs as drug targets for CNS immune disorders.
    Hebb AL; Robertson HA
    Curr Opin Investig Drugs; 2008 Jul; 9(7):744-53. PubMed ID: 18600580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
    Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
    J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclic nucleotide phosphodiesterases and vascular smooth muscle.
    Polson JB; Strada SJ
    Annu Rev Pharmacol Toxicol; 1996; 36():403-27. PubMed ID: 8725396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychopharmacology and clinical practice.
    Glod CA
    Nurs Clin North Am; 1991 Jun; 26(2):375-99. PubMed ID: 1675462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.
    Xu Y; Zhang HT; O'Donnell JM
    Handb Exp Pharmacol; 2011; (204):447-85. PubMed ID: 21695652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs for psychiatric disorders.
    Med Lett Drugs Ther; 1991 May; 33(844):43-50. PubMed ID: 1674103
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pregnancy and psychiatric disorders].
    Szász A; Kovács Z
    Ideggyogy Sz; 2002 Jan; 55(1-2):50-3. PubMed ID: 12122945
    [No Abstract]   [Full Text] [Related]  

  • 37. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for psychiatric disorders.
    Med Lett Drugs Ther; 1994 Oct; 36(933):89-96. PubMed ID: 7935156
    [No Abstract]   [Full Text] [Related]  

  • 39. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-Acylhydrazones as inhibitors of PDE10A.
    Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.